Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and ...

Even a minor scratch from a potentially rabid animal requires immediate medical attention. According to Dr. Neha Rastogi Panda, Consultant-Infectious Diseases at Fortis Memorial Research Institute, ...

Cidara Therapeutics was initiated with a Market Outperform at Citizens, on potential of the company's lead candidate for influenza prevention. Read more here.

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

Utilizing syringe service programs to provide comprehensive PrEP care shows promise for encouraging more people who inject ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.